Novartis | NOVN - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
AbbVie USD 7.61B 2.04B 2026-06
Alcon AG USD 240M 24M 2026-03
Almirall EUR 30.32M 22M 2025-12
Amgen USD 2.08B 570M 2026-03
AstraZeneca USD 4.81B 894M 2026-06
Autolus Therapeutics Ltd USD -70.73M 20.78M 2026-03
Bayer EUR 321M 2.67B 2026-06
Biogen USD 647.3M 269.6M 2026-06
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Eli Lilly USD 8.85B 583.8M 2026-03
Fresenius EUR 535M 42M 2026-06
Fresenius Medical Care EUR 383M 43M 2026-06
Genmab DKK 295M 221M 2026-06
Gilead Sciences USD -7.53B 10.11B 2026-06
GlaxoSmithKline GBP 2.68B 532M 2026-06
GRIFOLS EUR 247M 135M 2026-06
Hikma Pharmaceutical USD 147.5M 3.5M 2025-06
J&J USD 8.66B 839M 2026-06
Lakefront Biotherapeutics EUR 13.96M 769.2M 2026-03
Lonza CHF 624M 197M 2024-12
Merck EUR 869M 468M 2026-03
Merck USD -3.53B 6.95B 2026-03
Novartis USD 4.27B 430M 2026-06
Novartis USD 3.84B 1.33B 2026-03
Novo Nordisk DKK 33.8B 3.23B 2025-06
Orion EUR 113.4M 213.6M 2026-03
Pfizer USD -653M 5.84B 2026-06
Philips EUR 546M 356M 2026-06
Recordati EUR 161.16M 39.6M 2026-06
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Roche Holding CHF 11.17B 6.38B 2026-06
Sanofi EUR 837M 1.17B 2026-06
UCB EUR 789M 427M 2025-06